Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2

Douglas F. Lake, Alexa J. Roeder, Erin Kaleta, Paniz Jasbi, Sivakumar Periasamy, Natalia Kuzmina, Alexander Bukreyev, Thomas Grys, Liang Wu, John R Mills, Kathrine McAulay, Maria Gonzalez-Moa, Alim Seit-Nebi, Sergei Svarovsky
doi: https://doi.org/10.1101/2020.12.15.20248264
Douglas F. Lake
1School of Life Sciences, Arizona State University, Tempe AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: douglas.lake@asu.edu
Alexa J. Roeder
1School of Life Sciences, Arizona State University, Tempe AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin Kaleta
2Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paniz Jasbi
3College of Health Solutions, Arizona State University, Phoenix AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivakumar Periasamy
4Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX USA
5Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Kuzmina
4Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX USA
5Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Bukreyev
4Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX USA
5Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX USA
6Department of Microbiology and Immunology University of Texas Medical Branch at Galveston, Galveston, TX USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Grys
2Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liang Wu
7Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology, Rochester, MN USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R Mills
7Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology, Rochester, MN USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrine McAulay
2Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Gonzalez-Moa
8Axim Biotechnologies Inc, San Diego, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alim Seit-Nebi
8Axim Biotechnologies Inc, San Diego, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergei Svarovsky
8Axim Biotechnologies Inc, San Diego, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

As increasing numbers of people recover from and are vaccinated against COVID-19, tests are needed to measure levels of protective, neutralizing antibodies longitudinally to help determine duration of immunity. We developed a lateral flow assay (LFA) that measures levels of neutralizing antibodies in plasma, serum or whole blood. The LFA is based on the principle that neutralizing antibodies inhibit binding of the spike protein receptor-binding domain (RBD) to angiotensin-converting enzyme 2 (ACE2). The LFA compares favorably with authentic SARS-CoV-2 and pseudotype neutralization assays with an accuracy of 98%. Sera obtained from patients with seasonal coronaviruses did not prevent RBD from binding to ACE2. To demonstrate the usefulness of the LFA for measuring antibodies in convalescent plasma used for therapy, we measured conversion of non-immune plasma into strongly neutralizing plasma. This is the first report of a neutralizing antibody test that is rapid, highly portable and relatively inexpensive that might be useful in assessing COVID-19 vaccine-induced immunity.

Competing Interest Statement

AJR, EK, PJ, SP, NK, AB, TG, LW, JRM and KM have no competing interests. DFL received support from Axim Biotechnologies to perform the study. SS and AS-N are supported and employed by Axim Biotechnologies.

Funding Statement

Axim Biotechnologies supported this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Peripheral blood, serum and plasma were collected for this study under an Arizona State University IRB approved protocol #0601000548 and Mayo Clinic IRB protocol #20-004544.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data in the manuscript is available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 05, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2
Douglas F. Lake, Alexa J. Roeder, Erin Kaleta, Paniz Jasbi, Sivakumar Periasamy, Natalia Kuzmina, Alexander Bukreyev, Thomas Grys, Liang Wu, John R Mills, Kathrine McAulay, Maria Gonzalez-Moa, Alim Seit-Nebi, Sergei Svarovsky
medRxiv 2020.12.15.20248264; doi: https://doi.org/10.1101/2020.12.15.20248264
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2
Douglas F. Lake, Alexa J. Roeder, Erin Kaleta, Paniz Jasbi, Sivakumar Periasamy, Natalia Kuzmina, Alexander Bukreyev, Thomas Grys, Liang Wu, John R Mills, Kathrine McAulay, Maria Gonzalez-Moa, Alim Seit-Nebi, Sergei Svarovsky
medRxiv 2020.12.15.20248264; doi: https://doi.org/10.1101/2020.12.15.20248264

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (196)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (90)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5688)
  • Forensic Medicine (3)
  • Gastroenterology (216)
  • Genetic and Genomic Medicine (868)
  • Geriatric Medicine (88)
  • Health Economics (231)
  • Health Informatics (762)
  • Health Policy (392)
  • Health Systems and Quality Improvement (254)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6485)
  • Intensive Care and Critical Care Medicine (391)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (93)
  • Neurology (848)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (163)
  • Occupational and Environmental Health (261)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (106)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (114)
  • Psychiatry and Clinical Psychology (968)
  • Public and Global Health (2231)
  • Radiology and Imaging (377)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)